Sector News

Sarepta names former Allergan executive as new CEO

June 29, 2017
Life sciences

Sarepta Therapeutics, the Cambridge biotech that won approval last year for the first-ever Duchenne muscular dystrophy drug, said Wednesday that it had appointed former Allergan executive Douglas Ingram as its new CEO.

Sarepta had been searching for a new CEO after Ed Kaye announced in April that he planned to step down. Ingram served as president of Allergan until the company was acquired by Actavis in 2015. More recently, he was CEO of Chase Pharmaceuticals, a California biotech focused on neurodegenerative diseases that was sold to Allergan in November 2016 for $125 million upfront.

Kaye was named interim CEO of Sarepta in March 2015 and took on the job permanently in September 2016. He helped Sarepta win approval for the first-ever Duchenne treatment, Exondys 51, despite limited clinical data. Lingering doubts about the drug’s efficacy, coupled with its high price tag, have led to disputes over reimbursement, though the company has said that sales are strong thus far.

“Sarepta has a mission that matters, a deep pipeline to support that mission, and employees and a board that are single-mindedly focused on success through improving the lives of those with devastating rare diseases,” Ingram said in a statement Wednesday. “We will remain committed to the continued success of EXONDYS 51, and rapidly advancing our clinical pipeline and next-generation platform technology.”

According to Sarepta, Ingram will also serve on the company’s board.

Source: Boston Business Journal

Related News

October 24, 2020

Neutralising the gluten threat: are we on the cusp of a coeliac disease breakthrough?

Life sciences

Coeliac disease causes long-term damage to patients’ small intestine and puts them at risk of other medical conditions. Treatment options are urgently needed. Allie Nawrat explores the promise of larazotide, the drug in development currently leading the pack.

October 24, 2020

Bone Therapeutics showcases allogeneic cell therapy data

Life sciences

Bone Therapeutics has announced positive 24-month follow-up results from its phase IIa study of Allob, its allogeneic cell therapy, in patients undergoing lumbar spinal fusion procedures.

October 24, 2020

UCB acquires new campus to support UK operations

Life sciences

Belgian pharma company UCB has agreed to acquire a new campus to further support its operations in the UK.

Send this to a friend